PHRRF Stock Chart & Stats
$0.04
<$0.01(28.21%)
At close: 4:00 PM EDT
$0.04
<$0.01(28.21%)
Day’s Range― - ―
52-Week Range$0.03 - $0.12
Previous CloseN/A
Volume58.18K
Average Volume (3M)80.24K
Market Cap
$3.56M
Enterprise Value$9.70M
Total Cash (Recent Filing)$921.54K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume36,095
30 Day Avg. Volume80,239
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)8.91
Price to Sales (P/S)0.00
P/FCF Ratio-11.26
Enterprise Value/Market Cap2.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$59.52M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of total debt reduces refinancing pressure and interest obligations, giving PharmaTher greater flexibility while its development programs mature. Low leverage also limits creditor claims on future cash flows, although the company still needs sufficient funding to support operations and commercialization.
Narrowing Net LossesThe substantial reduction in annual net losses indicates improving cost control and a potentially more disciplined operating structure. If maintained, this trajectory could extend the company’s funding runway and reduce the scale of capital required before its development programs generate revenue.
Reduced Operating Cash BurnLower operating cash burn is a constructive sign for near-term financial durability because fewer resources are being consumed to maintain operations. Continued improvement would lessen reliance on external funding and preserve more capital for advancing ketamine-based therapeutic programs.
Bears Say
Pre-Revenue Business ModelWith no reported revenue across the available annual periods, PharmaTher has not yet demonstrated a recurring commercial revenue base. This leaves future financial performance dependent on successful development, approvals, and commercialization of its ketamine-focused programs.
Persistent Cash BurnPersistent negative operating and free cash flow means the business continues to consume cash rather than fund itself internally. This can constrain investment in development and commercialization, while making continued access to external funding important for sustaining operations.
Shrinking Equity BaseThe sharp erosion of stockholders’ equity shows that cumulative losses or capital outflows have materially reduced the company’s financial base. A smaller equity cushion limits resilience against setbacks and reduces flexibility to fund research, regulatory work, and commercialization internally.
PharmaTher Holdings Ltd News
PHRRF FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was $0.03 and its highest was $0.12 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is $3.56M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Oct 28, 2026 which is in 4 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
PharmaTher Holdings Ltd released its earnings results on Jan 30, 2026. The company reported -$0.002 earnings per share for the quarter.
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd does not currently pay dividends.
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 91,019,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
PharmaTher Holdings Ltd reported an EPS of -$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in PHRRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
BetterLife Pharma
―
BioVaxys Technology
―
Marvel Biosciences Corp
―
Ownership Overview
0.44% Insiders
<0.01% Other Institutional Investors
99.56% Public Companies and
Individual Investors